动态对比增强序列在多参数前列腺MRI中的附加价值:PROMIS研究数据
PROMIS多中心多读者试验中,497例活检初治男性接受标准化1.5T多参数MRI(T2、弥散、DCE)后行5mm间距经会阴前列腺映射活检。按T2+弥散及再加DCE顺序评分,加用DCE后敏感度94%升至95%、特异度37%升至38%,各指标差异均无统计学意义,提示DCE在排除显著前列腺癌时附加价值有限。
要点
- 加用DCE后敏感度95%、特异度38%,与不加DCE的94%、37%相比差异无统计学意义。
- 避免活检人数相似(121/497对123/497),DCE未显著减少不必要穿刺。
- DCE未遗漏任何优势Gleason 4分及以上肿瘤,T2+弥散遗漏1例。
核心结论
- 多参数MRI用于排除显著前列腺癌时,加用DCE序列附加价值很小。
研究设计与样本
- PROMIS为多中心、多读者试验,本部分纳入497例活检初治男性。
- 受试者接受标准化1.5T多参数MRI(T2、弥散、DCE),随后行5mm间距经会阴前列腺映射活检。
- 按严格顺序先评T2+弥散、再评T2+弥散+DCE,Likert评分1-5分。
主要发现
- 不加与加DCE的敏感度分别为94%和95%,特异度37%和38%,阳性预测值均为51%,阴性预测值90%和91%(各比较P>0.05)。
- 评分为1-2分而避免活检者分别为123/497和121/497(P=0.8)。
- 不确定评分(3/5分)在不加DCE时略高(32%对28%,P=0.031)。
- MRI不确定(3/5分)和阳性(4-5分)病例中显著肿瘤比例相似(23%和71%对20%和69%)。
- DCE未遗漏任何优势Gleason 4分及以上肿瘤,T2+弥散加权成像遗漏1例。
关键数值与推荐
- 主要分析采用PROMIS主要结局指标:映射活检Gleason评分≥4+3或最大癌长≥6mm。
- MRI评分≥3分定义为阳性。
临床怎么用
- 在多参数MRI用于排除显著前列腺癌时,可考虑省略DCE序列。
局限性
- 未尝试将MRI病灶位置与组织学进行对应。
- 放射科医生知晓患者前列腺特异性抗原水平。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multiparametric magnetic resonance imaging (MP-MRI) is established in the diagnosis of prostate cancer, but the need for enhanced sequences has recently been questioned. OBJECTIVE: To assess whether dynamic contrast-enhanced imaging (DCE) improves accuracy over T2 and diffusion sequences. DESIGN, SETTING, AND PARTICIPANTS: PROMIS was a multicentre, multireader trial, with, in this part, 497 biopsy-naïve men undergoing standardised 1.5T MP-MRI using T2, diffusion, and DCE, followed by a detailed transperineal prostate mapping (TPM) biopsy at 5 mm intervals. Likert scores of 1-5 for the presence of a significant tumour were assigned in strict sequence, for (1) T2 + diffusion and then (2) T2 + diffusion + dynamic contrast-enhanced images. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: For the primary analysis, the primary PROMIS outcome measure (Gleason score ≥4 + 3 or ≥6 mm maximum cancer length) on TPM was used, and an MRI score of ≥3 was considered positive. RESULTS AND LIMITATIONS: Sensitivity without and with DCE was 94% and 95%, specificity 37% and 38%, positive predictive value 51% and 51%, and negative predictive value 90% and 91%, respectively (p > 0.05 in each case). The number of patients avoiding biopsy (scoring 1-2) was similar (123/497 vs 121/497, p = 0.8). The number of equivocal scores (3/5) was slightly higher without DCE (32% vs 28% p = 0.031). The proportion of MRI equivocal (3/5) and positive (4-5) cases showing significant tumours were similar (23% and 71% vs 20% and 69%). No cases of dominant Gleason 4 or higher were missed with DCE, compared with a single case with T2 + diffusion-weighted imaging. No attempt was made to correlate lesion location on MRI and histology, which may be considered a limitation. Radiologists were aware of the patient's prostate-specific antigen. CONCLUSIONS: Contrast adds little when MP-MRI is used to exclude significant prostate cancer. PATIENT SUMMARY: An intravenous injection of contrast may not be necessary when magnetic resonance imaging is used as a test to rule out significant tumours in the prostate.
引用
- Bosaily AE, Frangou E, Ahmed HU, et al. Additional Value of Dynamic Contrast-enhanced Sequences in Multiparametric Prostate Magnetic Resonance Imaging: Data from the PROMIS Study. Eur Urol. 2020. PMID: 32312543. doi:10.1016/j.eururo.2020.03.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。